Abstract
Psoriasis is an immune-mediated disease with a chronic relapsing course, and the particularly severe forms that are refractory to traditional therapies are often difficult to manage. Everolimus (Certican®; Novartis, Basel, Switzerland) is a new rapamycin-derived macrolide that is used in the prophylaxis of rejection in heart and kidney transplant patients. The mechanism underlying its immunosuppressant and antiproliferative activity is different from, but complementary to, that of calcineurin inhibitors such as ciclosporin. We describe a woman with severe psoriasis treated with everolimus combined with subtherapeutic doses of ciclosporin.
| Original language | English |
|---|---|
| Pages (from-to) | 372-374 |
| Number of pages | 3 |
| Journal | British Journal of Dermatology |
| Volume | 156 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2007 |
Keywords
- Ciclosporin
- Everolimus
- Psoriasis
ASJC Scopus subject areas
- Dermatology
Fingerprint Dive into the research topics of 'Severe psoriasis treated with a new macrolide: Everolimus'. Together they form a unique fingerprint.
Cite this
Frigerio, E., Colombo, M. D., Franchi, C., Altomare, A., Garutti, C., & Altomare, G. F. (2007). Severe psoriasis treated with a new macrolide: Everolimus. British Journal of Dermatology, 156(2), 372-374. https://doi.org/10.1111/j.1365-2133.2006.07602.x